Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ERAS Erasca Inc

-0.005 (-0.22%)
Last Updated: 11:47:55
Delayed by 15 minutes


Draw Mode:

Volume 541,948
Bid Price 2.23
Ask Price 2.24
News -
Day High 2.29


52 Week Range


Day Low 2.18
Company Name Stock Ticker Symbol Market Type
Erasca Inc ERAS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.005 -0.22% 2.235 11:47:55
Open Price Low Price High Price Close Price Prev Close
2.22 2.18 2.29 2.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,957 541,948 $ 2.22 $ 1,201,990 - 1.51 - 3.375
Last Trade Time Type Quantity Stock Price Currency
11:48:01 2 $ 2.235 USD

Erasca Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
336.92M 151.09M - 0 -125.04M -0.83 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Erasca News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ERAS Message Board. Create One! See More Posts on ERAS Message Board See More Message Board Posts

Historical ERAS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.012.301.812.104,888,3120.22511.19%
1 Month1.852.301.812.081,600,0920.38520.81%
3 Months2.422.6551.742.141,068,009-0.185-7.64%
6 Months2.282.6551.512.011,143,388-0.045-1.97%
1 Year2.783.3751.512.20882,876-0.545-19.60%
3 Years15.9024.471.515.80749,228-13.67-85.94%
5 Years15.9024.471.515.80749,228-13.67-85.94%

Erasca Description

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.

Your Recent History

Delayed Upgrade Clock